JP2023522208A5 - - Google Patents

Info

Publication number
JP2023522208A5
JP2023522208A5 JP2022562984A JP2022562984A JP2023522208A5 JP 2023522208 A5 JP2023522208 A5 JP 2023522208A5 JP 2022562984 A JP2022562984 A JP 2022562984A JP 2022562984 A JP2022562984 A JP 2022562984A JP 2023522208 A5 JP2023522208 A5 JP 2023522208A5
Authority
JP
Japan
Prior art keywords
dose
during
composition according
week
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/027636 external-priority patent/WO2021211940A1/en
Publication of JP2023522208A publication Critical patent/JP2023522208A/ja
Publication of JP2023522208A5 publication Critical patent/JP2023522208A5/ja
Pending legal-status Critical Current

Links

JP2022562984A 2020-04-16 2021-04-16 ウイルスによって引き起こされる補体媒介性障害を処置する方法 Pending JP2023522208A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063010905P 2020-04-16 2020-04-16
US63/010,905 2020-04-16
US202063014999P 2020-04-24 2020-04-24
US63/014,999 2020-04-24
US202063019050P 2020-05-01 2020-05-01
US63/019,050 2020-05-01
US202063020195P 2020-05-05 2020-05-05
US202063020286P 2020-05-05 2020-05-05
US63/020,195 2020-05-05
US63/020,286 2020-05-05
US202063033140P 2020-06-01 2020-06-01
US63/033,140 2020-06-01
US202063063538P 2020-08-10 2020-08-10
US63/063,538 2020-08-10
PCT/US2021/027636 WO2021211940A1 (en) 2020-04-16 2021-04-16 Methods for treating a complement mediated disorder caused by viruses

Publications (2)

Publication Number Publication Date
JP2023522208A JP2023522208A (ja) 2023-05-29
JP2023522208A5 true JP2023522208A5 (cg-RX-API-DMAC7.html) 2024-09-09

Family

ID=75787341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562984A Pending JP2023522208A (ja) 2020-04-16 2021-04-16 ウイルスによって引き起こされる補体媒介性障害を処置する方法

Country Status (5)

Country Link
US (1) US20230416344A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135837A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023522208A (cg-RX-API-DMAC7.html)
CN (1) CN116406287A (cg-RX-API-DMAC7.html)
WO (1) WO2021211940A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CA3161271A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗c5a抗體
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下(sc)施用抗c5抗体治疗补体相关病症
JP7821160B2 (ja) * 2020-08-13 2026-02-26 アレクシオン ファーマシューティカルズ, インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与
WO2024121370A1 (en) * 2022-12-09 2024-06-13 Universität Zürich Complement component 7 as a diagnostic marker and therapeutic target
US12180274B2 (en) * 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
WO2025221479A1 (en) * 2024-04-16 2025-10-23 Alexion Pharmaceuticals, Inc. Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201691481A1 (ru) * 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
IL307197B2 (en) 2017-07-11 2026-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
US20200230408A1 (en) * 2018-12-21 2020-07-23 Electrocore, Inc. Systems and methods for treating patients with diseases associated with replicating pathogens
WO2019227102A1 (en) * 2018-05-25 2019-11-28 Achillion Pharmaceuticals, Inc. Complement alternative pathway-associated nephropathy biomarkers
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
EP3852874A1 (en) * 2018-09-17 2021-07-28 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure

Similar Documents

Publication Publication Date Title
US11325972B2 (en) Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody
JP2020183389A5 (cg-RX-API-DMAC7.html)
JP5954916B1 (ja) Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
KR20170015517A (ko) 혈액 응고 제 viii 인자 및/또는 활성화 혈액 응고 제 viii 인자의 활성의 저하 내지 결손에 의해 발증 및/또는 진전되는 질환의 예방 및/또는 치료에 이용되는 의약 조성물
US10555713B2 (en) Methods for treating idiopathic pulmonary fibrosis
JP2021525718A5 (cg-RX-API-DMAC7.html)
WO2021211940A1 (en) Methods for treating a complement mediated disorder caused by viruses
US20240209097A1 (en) Treatment regimens
WO2023175035A1 (en) Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
Kaya et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia: A single-center observational study
WO2019089147A1 (en) Methods of treating didiopathic pulmonary fibrosis
JP2023521909A (ja) 呼吸器疾患の治療
JP2023521592A (ja) サイトカインストーム症候群の治療のためのペプチド
Khoshfetrat et al. A Comparison of Premedication Injections of Magnesium Sulfate, Ketamine and Lidocaine on the severity of Pain Induced by Intravenous Injection of Propofol
US20200055942A1 (en) Treatment regimens
WO2019025847A1 (en) TREATMENT DIAGRAMS
Mahdavi et al. Comparative Effects of Premedication With Acetaminophen Versus Ketorolac on Postoperative Pain in 4–7-Year-Old Children Undergoing Dental Treatment Under General Anesthesia: A Parallel Triple-Blind Randomized Clinical Trial
Kim et al. The comparative effects of S-amlodipine versus racemic amlodipine on long-term cardiovascular outcomes in subjects with hypertension: a nationwide population-based cohort study
WO2021185838A1 (en) New therapeutic use of anakinra for covid-19
WO2025238225A1 (en) Methods of treating osteoarthritis and osteoarthritis pain with an anti complement c2 antagonistic antibody
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
Lang et al. Management of comorbidities in heart failure
WO2021255438A1 (en) Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome
Lang et al. in Heart Failure
Spiegler Site of Central Venous Catheterization: Does It Matter?